A case report says a woman with advanced Alzheimer’s began holding extended conversations about her past roughly 19 hours after ingesting psilocybin-containing mushrooms.
The reported change reached far beyond speech. She also regained urinary control, walked without help, dressed herself and showed more recognition and initiative. But this was one patient, not a randomized trial, and the authors say the result does not prove that Alzheimer’s disease was reversed.
That caution matters because the patient did not have formal biomarker confirmation or advanced imaging. The researchers also say a vascular or mixed contribution to her condition cannot be completely ruled out.
Her condition had declined for years
The Japanese-American woman, who was in her 80s, had a 10-year clinical history of Alzheimer’s disease. For about five years, she had mostly spoken in single syllables, needed help to walk and remained under constant family and caregiver supervision.
She also had urinary incontinence, difficulty swallowing, limited facial expression, little spontaneous communication and could not dress herself. With her son’s consent, she received 5 grams of dried Enigma-strain Psilocybe cubensis by mouth. That was the weight of the mushrooms, not 5 grams of purified psilocybin.
The first hours were troubling. She sweated heavily and entered a prolonged state resembling deep sleep, while clinicians suspected hyperthermia. Then, at about 3:30 a.m., she woke on her own.
The change appeared across several abilities
According to the report, she began speaking about personal memories and reflections for roughly four hours. Her son said he had not heard her produce that kind of material in years.
Over the next few days, her speech moved from isolated syllables to spontaneous conversation. Her long-standing incontinence stopped, including overnight. She walked without assistance by the second day and began dressing herself and taking initiative within two or three days.
She also made eye contact, smiled in response, recognized relatives and recalled contextual details, including asking where someone had gone and recognizing a rented car. One month later, the authors said she remained continent and continued to function above her earlier baseline.
A social media post about the case highlighted the wide range of reported changes:
This is insane…
An advanced Alzheimer’s patient just REGAINED her memory, speech, mobility, AND bladder control after a SINGLE dose of psilocybin.
There are NO Alzheimer’s drugs capable of doing anything CLOSE to this. pic.twitter.com/m8qzMrNsFk
— Nicolas Hulscher, MPH (@NicHulscher) October 1, 2026
A second session brought more expression
The team later supervised another session using 3 grams. During it, she reportedly showed more facial expression, spontaneous humor and verbal energy. She also walked more easily and described surfing with her son on a peaceful island.
In follow-up, the patient was quoted as saying, “It is pleasant to come here.” No severe lasting adverse effects, persistent psychosis, major cardiovascular instability or delayed neurological decline were reported.
The paper, published in Frontiers in Neuroscience on May 28, 2026, still leaves major questions unanswered. The authors note that dementia symptoms can fluctuate naturally and that the case lacked standardized cognitive testing, EEG, sleep studies and imaging that could help explain the mechanism.
They describe the finding as a possible temporary access to residual function under certain neuromodulatory conditions, not evidence that brain plaques disappeared or that the disease was cured.
The report also comes amid broader interest in psychedelic research. The Gateway Pundit reported that President Trump signed an April 2026 executive order directing the FDA to develop guidance for clinical trials involving psilocybin, ibogaine, LSD and MDMA. The order also called for NIH support for additional studies, particularly involving veterans and PTSD, while the substances remain Schedule I outside approved research.
Source: The Gateway Pundit
